121 results about "Metabolic Marker" patented technology

The invention discloses a determination method of a urine metabolic marker for early diagnosis of diabetic nephropathy. The method mainly utilizes analysis technique and method such as gas mass spectrometry and mass liquid spectrometry for quantitative determination of endogenous small molecule compounds in urine of patients with diabetes and diabetic nephropathy; and relative concentration difference between endogenous small molecule compounds in a pathological group and a normal group is calculated and compared, so as to be applied to clinical early diagnosis of diabetic nephropathy. Compared with other existing clinical diagnosis indexes, the method has advantages of wide adaptation range, sensitivity, simple sampling and operation, and no harm on the body. The method is more suitable for screening of diabetic nephropathy in early stage with some uncertain physiological and biochemical indexes, so as to avoid missing of the best treatment time due to delayed diagnosis.

The invention discloses a determination method of a serum metabolic marker for early diagnosis of diabetic nephropathy. The method mainly utilizes analysis technique and method such as gas mass spectrometry and mass liquid spectrometry for quantitative determination of endogenous small molecule compounds in urine of patients with diabetes and diabetic nephropathy; and relative concentration difference between endogenous small molecule compounds in a pathological group and a normal group is calculated and compared, so as to be applied to clinical early diagnosis of diabetic nephropathy. Compared with other existing clinical diagnosis indexes, the method has advantages of wide adaptation range, sensitivity, simple sampling and operation, and no harm on the body. The method is more suitable for screening of diabetic nephropathy in early stage with some uncertain physiological and biochemical indexes, so as to avoid missing of the best treatment time due to delayed diagnosis.

The invention discloses a metabolic marker combination for evaluating the risks of cardiovascular and cerebrovascular disease of a subject. The metabolic marker combination comprises ceramide Cer d18:1 / 16:0, ceramide Cer d18:1 / 18:0, ceramide Cer d18:1 / 24:0, phenylacetyl glutamine, trimethylamine, glycine betaine and choline. The cardiovascular and cerebrovascular diseases are selected from coronary heart disease, atherosclerosis, atrial fibrillation and heart failure. The metabolic marker combination disclosed by the invention has the advantages of high sensitivity, good specificity, quantification, high detection flux and the like in the aspect of evaluating or predicting the risks of cardiovascular and cerebrovascular diseases.

The invention belongs to the technical field of metabonomics, and provides Xiaoyao San metabolic markers in a biological sample, and a detection method and an application thereof. A pharmacological action mechanism of Xiaoyao San for treating depression is defined. The metabolic markers are 4-oxo hex-2-ene dioic acid, creatinine, L-cystathionine and acetylphosphate. A UPLC-Q-TOF / MS technology is adopted for analyzing the plasma and metabolic profile change of patients in a drug administration group and a control group of the Xiaoyao San, and then a multivariate statistical analysis method and an orthogonal partial least square discriminant analysis (OPLS-DA) method are adopted for screening the changes of the metabolic markers of the Xiaoyao San after 8-week treatment. The study is used as a first clinical metabonomics study of the Xiaoyao San; the influence of the metabolic level of the Xiaoyao San is found; the action mechanism of the Xiaoyao San is preliminarily illuminated in metabolic pathway; and a new method is provided for predicting the pharmacological mechanism of the Xiaoyao San for treating the depression.

The invention discloses a metabolomics-based pancreatic cancer diagnosis marker and a screening method thereof. The diagnosis marker comprises any one or a combination of more of 31 plasma metabolic markers. The invention also provides a method for constructing a diagnosis model by using the pancreatic cancer diagnosis marker and an application in a diagnosis kit. According to the method, non-target metabolomics analysis is carried out on the plasma of a patient through a high-efficiency liquid chromatography mass spectrometry technology, the difference metabolite between the pancreatic cancerpatient and the normal people is found through an artificial intelligence data analysis technology, and the diagnosis capability of the specific differential metabolite, namely the pancreatic cancerdiagnosis marker in the diagnosis of the pancreatic cancer is further verified through target metabolomics analysis and machine learning modeling.

The invention provides a use of a blood metabolism marker and a depression detecting kit. The blood metabolism marker can be used for preparing a reagent or an apparatus for diagnosing depression, for example a kit which comprises standard pure liquor with concentration being 10mg / ml of the metabolism marker, 13C stable isotope internal standard liquor, methanol-aqueous solution with a volume ratio being 1 to 1, one analytical chromatographic column and quality control standard serum; the kit can be used for accurately measuring content of 14 screened metabolism markers in blood, and is utilized for early diagnosing the depression with specificity being 86.8%, sensitivity being 96.8% and accuracy rate being 93.0%, so that the diagnosis of the depression does not depend on a questionnaire completely for subjective judgment, and therefore, the diagnosis accuracy is greatly improved.

The invention discloses a metabolic marker for diagnosing a coronary heart disease. The metabolic marker comprises one or more of 1-palmitoyl-sn-glycerinum-3-phosphatidylcholine, 1-octadecatetraenoicenoyl-sn-glycerinum-3-phosphatidylcholine, 1-linoleoyl-sn-glycerinum-3-phosphatidylcholine, 1-stearoyl-sn-glycerinum-3-phosphatidylcholine, 1-linoleoyl-2-hydroxy-sn-glycerinum-3-phosphatidyl ethanolamine, 1-linoleoyl-sn-glycerinum-3-phosphatidylcholine, 1-oleoyl-sn-glycerinum-3-phosphatidylcholine, 1-hexadecene acyl-sn-glycerinum-3-phosphatidylcholine, phytosphingosine and hexadecanamide. The metabolic marker provided by the invention can accurately diagnose the coronary heart disease, accurately distinguish patients with the coronary heart disease and healthy persons, can also accurately distinguish the patients with the coronary heart disease from patients with atherosclerosis of coronary artery, and has high accuracy, sensitivity and specificity.

The invention discloses a serum metabolic marker for tuberculosis drug resistance diagnosis and application thereof. The serum metabolite is selected from at least one of 30 serum metabolite such as stearoyl glutamic acid; analysis is performed according to the serum metabolite of individuals with different tuberculosis drug resistance types; and a novel thought is provided for tuberculosis drug resistance diagnosis from the perspective of the serum metabolite.

The present invention provides metabolic markers and targets, especially PEMT activity and metabolic markers and components associated therewith useful for diagnosing and treating various disease conditions.

The invention belongs to the technical field of clinical medical diagnosis and relates to a screening method of early-stage liver cancer diagnosis markers for people with liver cirrhosis and hepatitis. The screening method of the early-stage liver cancer diagnosis markers for people with liver cirrhosis and hepatitis liver cirrhosis and hepatitis comprises the following steps of: S1, acquiring data, specifically, collecting a target plasma sample and detecting metabolites in the plasma sample; S2, constructing a discrimination model used for distinguishing people with liver cirrhosis from patients with the primary liver cancer and distinguishing people with the hepatitis from patients with the primary liver cancer; S3, screening markers; and S4, verifying diagnosis capability. According to the screening method of early-stage liver cancer diagnosis markers for people with liver cirrhosis and hepatitis, a high performance liquid chromatography-mass spectrometry system is utilized to obtain the metabolic profiles of blood plasma of patients with liver cirrhosis, hepatitis and hepatocellular carcinoma, a potential tumor metabolic marker group is found, and a diagnosis model is constructed and is used for assisting early diagnosis of tumors of groups with high risk of liver cancer.

The invention provides a method for screening for and detection of diabetes mellitus in a subject that comprises assaying a test sample of urine from the subject for a metabolic marker of diabetes. An elevated or reduced amount of marker present in the test sample compared to a control sample is indicative of diabetes. The method can be used to screen for gestational diabetes early in pregnancy, or to detect diabetes or susceptibility to diabetes, in pregnant or non-pregnant subjects.

The invention relates to a biomarker for preoperative identification of benign and malignant thyroid nodules, a kit and application thereof. The level of 17 metabolites in peripheral blood plasma of a thyroid nodule patient is detected through metabonomics analysis, and omics analysis and a machine learning method are combined to construct a diagnosis model and evaluate the thyroid cancer diagnosis efficiency by using a subject working curve (ROC). The area of the metabolic marker combination diagnosis model composed of the metabolites under the ROC curve in thyroid nodule diagnosis can reach 95.05%, the sensitivity and specificity are both higher than 88%, and the metabolite marker combination diagnosis model can be applied to identification of thyroid benign and malignant nodules.

The present invention belongs to the technical field of screening and identification of nephrotic syndrome markers, and provides nephrotic syndrome progression-related metabolic markers and application thereof. Bis(4-ethylbenzyl)sorbitol, C16 d-sphinganine, lysophosphatidylethanolamine (LPE) (22:6), lysophosphatidylcholine (LPC) (22:5), N-ethanolamine and proline are taken as progressive markers; oleic acid amide, docosahexaenoic acid, 14S-hydroxy-docosahexaenoic acid, docosapentaenoic acid, uric acid, and LPC (20:5) and (18:1) are taken as early markers; and acylcarnitine (C18:0), linoleic acid carnitine, LPC (18:3), DL-tryptophan, indoleacrylic acid, p-cresol sulfate, 3-indol sulfate, cytosine, creatinine, sphingosine-1-phosphoric acid, L-aleuritic-dihydrosphingosine and ceramide (d18:0 / 14:0) are taken as late markers. The nephrotic syndrome progression-related metabolic markers provided by the present invention can be quantified, are fast, and have high sensitivity and strong specificity.

Methods for monitoring the immune response and predicting clinical outcomes for patients on immunosuppressive drugs (such as transplant patients) are provided. The methods are based on the measurement of an intracellular metabolic marker in lymphocytes (such as ATP) as an indicator of a patient's immune response.

The invention relates to methods for the diagnosis of non-alcoholic steatosis (NASH). The method relies on the determination of certain metabolic markers in a biological sample of the patient which are up- or down-regulated in the NASH patients vs. patients with a simple fatty liver (steatosis).

The invention discloses a metabolic marker for diagnosis of coronary atherosclerosis. The metabolic marker includes one or more of 1-arachidonoyl-2-hydroxy-sn-glycerol-3-phosphatidylethanolamine, 1-eicosenoyl-2-hydroxy-sn-glycerol-3-phosphatidylethanolamine, 1-oleoyl-sn-glycerol-3-phosphatidylcholine, 1- docosahexanoyl-2-hydroxy-sn-glycerol-3-phosphatidylethanolamine, 1-docosapentanoyl-2-hydroxy-sn-glycerol-3-phosphatidylethanolamine, 1-docosapentanoyl-sn-glycerol-3-phosphatidylcholine, 1-stearoyl-sn-glycerol-3 phosphatidylcholine, 1-oleoyl-2-hydroxy-sn-glycerol-3-phosphatidylethanolamine, 1-palmitoyl-2-hydroxy-sn-glycerol-3-phosphatidylethanolamine, 1-palmitoyl-sn-glycerol-3-phosphatidylcholine, and 1-octadecanoyl-2-hydroxy-sn-glycerol-3-phosphatidylethanolamine. The metabolic marker provided by the invention can accurately diagnose and distinguish coronary atherosclerosis patients and healthy people, and has high accuracy, strong sensitivity and specificity.

The invention discloses a metabolic marker for diagnosing and distinguishing unstable angina pectoris and acute myocardial infarction, comprising one or more of N-phenylalanyl-L-glutamine, sphinganine, arachidonic acid, eicosatrienoic acid, glycocholic acid, lysophosphatidylcholine (14:0), tryptophan-arginine-leucine tripeptide, lysophosphatidylcholine (18:2), and lysophosphatidylcholine (20:3). In the single use of diagnosing and distinguishing patients with acute myocardial infarction and patients with unstable angina pectoris, each ROC (receiver operating characteristic) AUC (area under the curve) is greater than 0.7, and clinical diagnostic significance is provided; in the joint use for diagnosis, AUC further increases as a joint quantity increases, a highest AUC up to 0.991 is obtained in a case of nine members jointed, and sensitivity and specificity are respectively 99.2% and 98.9% under an optimal cutoff value. The metabolic marker can accurately diagnose and distinguish unstable angina pectoris and acute myocardial infarction, with high accuracy and high sensitivity and specificity.

The invention provides a metabolic marker for diagnosing or monitoring lung adenocarcinoma and a screening method and application of the metabolic marker. A metabolic marker system is selected from one or a combination of more of D-galactose, homocitrulline, N6-acetyl-L-lysine, 4-hydroxy-L-proline, hexadecanedioic acid, guanine, glutamic acid, creatine, alanine and kynuric acid. The metabolic marker provided by the invention can accurately diagnose a lung adenocarcinoma patient, can distinguish an early-stage lung adenocarcinoma patient from a healthy person, is high in sensitivity and strong in specificity, can well replace an existing tissue biopsy and imaging diagnosis mode, and reduces trauma and radiation risks.

The invention relates to a novel application of metabolites, namely galactose, 1, 5-sorbitan, N-acetyl glucosamine and 2-hydroxybutyric acid, in fasting serum as combined markers in preparation of a kit for rapidly diagnosing diabetic patients in subjects. Whether a subject suffers from diabetes mellitus or not is judged by detecting the concentrations of the four metabolites in an empty serum sample of the subject, the combined marker variable P is calculated based on a binary logistic regression equation and an intercept point value is judged, and whether the subject suffers from diabetes or not is judged. The kit can realize high-sensitivity and high-efficiency detection, and the small molecule metabolites involved in the invention have the characteristics of low detection cost and good repeatability. The kit can be applied to auxiliary rapid screening of diabetes people, has the characteristic of mutual complementation with the traditional clinical index fasting blood glucose, and has a relatively good application prospect.

The invention relates to a method for detecting small-molecule metabolic markers in the peripheral blood of aortic dissection, and its application. Combined chromatography and mass spectrometry are employed for high-flux large-scale metabonomic analysis of patients with aortic dissection to determine small-molecule metabolic profiling of the peripheral blood of the aortic dissection, and three small-molecule metabolic markers with greatest difference is obtained, wherein the three small-molecule metabolic markers are N1-acetyl-N2-formyl-5-methoxy kynurenine, glycerophosphorylcholine and 2-mercaptohistidine betaine. The invention provides a simple, low-harm and cheap method for screening and diagnosis of aortic dissection, and effective reference bases can be provided for diagnosis of clinical patients and assessment of the treatment efficacy of drugs.

The invention provides a use of a combined serum metabolic marker in the preparation of a kit for diagnosing the progress of hepatopathy, the kit, and a method using the kit to screen serum metabolicmarkers, and relates to the technical field of serum metabolic markers. The combined serum metabolic marker is mainly composed of sodium glycochenodeoxycholate sulfate, glycochenodeoxycholic acid, glycodesoxycholic acid, glycocholic acid and taurochenodeoxycholic acid. The kit executes combined screening detection on the content of above serum metabolites in serum in order to realize assisted diagnosis of the progress of the hepatopathy of hepatopathy patients, so the difficult monitoring problem of the occurrence and development of the hepatopathy in existing clinic therapy of the hepatopathyis effectively alleviated.

The invention discloses an application of a metabolic marker in atherosclerotic cerebral infarction, which comprises the following steps: collecting blood samples of atherosclerotic cerebral infarction and atherosclerotic patients, carrying out metabonomics analysis, and discovering metabolites with significant differences in two groups, therefore, the metabolite is utilized to predict early atherosclerotic cerebral infarction, and early treatment of a patient is further realized.

The invention discloses a marker group for diagnosing and distinguishing coronary arterial atherosclerosis from stable angina pectoris. The marker group comprises one or more of glutathione, beta-hydroxybutyric acid, proline, fumaric acid, phenylalanine and lactic acid. When a single marker is used for diagnosing and distinguishing patients with the stable angina pectoris from patients with the coronary arterial atherosclerosis, the AUCs (areas under curve) of a ROC (receiver operating characteristic) are all 0.7 or larger, and the marker has a clinical diagnosis significance; when the markers are used for diagnosis in combination, with the increase of the combination number, the AUC is further increased and reaches 0.988 when 6 markers are combined, and the sensitivity and the specificity are 98.5% and 98.3% respectively under the optimum cutoff value. The metabolic marker group can accurately diagnose and distinguish the coronary arterial atherosclerosis from the stable angina pectoris, and is high in sensitivity and specificity.

The present invention discloses a determination method and application of normal and different osteoporosis pathological process human serum difference metabolites. First, premenopause and post-menopause normal, osteopenia and osteoporosis patient serum are collected, serum metabolic compound original data is obtained by gas chromatography mass spectrometry analysis technique, SIMCAP-11 software is used to establish a multi-dimensional statistical model to find and identify serum difference metabolites in premenopause bone mass normal and post-menopause bone mass normal and bone mass initiation loss patients and osteoporosis patients, a plurality of difference metabolites in higher correlation with the osteoporosis pathological process can be further determined by use of correlation analysis and ROC curve analysis, a technical support for the early diagnosis and prevention of osteoporosis is provided, and patients in the early osteoporosis stage in which most of the physiological and biochemical indexes are not clear can be alerted.

The invention provides a novel diabetic kidney lesion detection kit, which can identify early-stage patients more sensitively, accurately, simply, conveniently and noninvasively by being compared withtraditional indexes, and can be used as one of novel clinical auxiliary diagnosis means. According to the invention, a UPLC-ESI-MS / MS (ultra-high performance liquid chromatography-electrospray ionization tandem mass spectrometry) method is used; nine novel serum metabolic markers that are related to early diabetic nephropathy and include hexadecanoic acid, delinoleic acid, azoxystrobin acid, lysophosphatidylcholine (20:4), piperidine, 6-methylmercaptopurine, 6-aminocaproic acid, L-hydrogenated orotic acid and cumin are screened out. Preliminary research data show that the group of metabolitescan diagnose patients with or without early diabetic kidney lesion through single or combined detection, a basis is provided for early intervention treatment of clinicians, and the occurrence of nephropathy at the final stage is reduced to the greatest extent.

The invention discloses metabolic markers related to low-grade glioma in urine and application of the metabolic markers. Specifically, in contrast to normal healthy people, the contents of metabolic markers including chenodeoxycholic sulfate, tyramine-oxygen-sulfate, glycochenodeoxycholic 3-glucosiduronide and aspartyl-leucine in urine of a low-grade glioma patient areincreased, and the contents of 2-hydroxy-ethyl sebacate, a deoxycholic acid and glycine conjugate and testosterone glucuronide are reduced. Therefore, an identification reagent of the metabolic markers related to the low-grade glioma can be used for preparing a product for diagnosis and / or prognosis of the low-grade glioma, the identification reagent is a mass spectrum identification reagent of the metabolic markers, and massspectrum identification is used under combination of mass spectrum full-scanning mode screening and secondary targeting identification; and the product is preferably used for early diagnosis of low-grade glioma.

The invention discloses an application of a metabolic marker in renal clear cell carcinoma. According to the invention, metabonomics analysis is carried out by collecting renal clear cell carcinoma and urine samples of normal people, and metabolites with significant differences in different groups are found, so that early renal clear cell carcinoma can be predicted by using the metabolites, and then personalized treatment of patients is realized.

The invention relates to a diagnostic marker, a kit and a screening method for esophageal cancer diagnosis and a construction method of an esophageal cancer diagnosis model, and belongs to the technical field of clinical examination and diagnosis. The diagnostic marker provided by the invention comprises any one or more of 44 serum metabolic markers. The diagnostic marker has good sensitivity andspecificity for esophageal cancer, can be used for esophageal cancer diagnosis (including early diagnosis), and has important significance for improving prognosis of esophageal cancer and increasing the survival rate of esophageal cancer patients.

The invention discloses a method for identifying metabolic markers based on heart Yang deficiency syndrome of coronary heart diseases. The method solves the problem that the existing clinical diagnosis method of heart Yang deficiency syndrome of coronary heart diseases has poor sensitivity so that the relationship between ingredients in the formula and curative effects is difficult to recover. Themethod comprises 1, carrying out UPLC analysis on n healthy subjects and n patient subjects suffering from heart Yang deficiency syndrome of coronary heart diseases through a UPLC-G2-Si-HDMS method to determine endogenous metabolites in serum samples, 2, carrying out full scanning on the endogenous metabolites in a positive and negative ion mode through a G2-Si-HDMS method to determine endogenousmetabolite structures and 3, identifying blood metabolic biomarkers of subjects suffering from heart Yang deficiency syndrome of coronary heart diseases. The method is used in the field of metabolicmarker identification.

The invention provides a metabolomics marker weight analysis universal method which comprises the following steps of S1, performing metabolite correlation analysis; S2, performing network analysis fordetermining a key metabolism network; S3, performing multiple regression analysis and determining a metabolic marker; and S4, based on network degree centrality, determining importance of the metabolic marker in the key metabolism network. According to the method of the invention, by means of network analysis, importance of the metabolic marker in the key metabolism network is quantified throughnetwork degree centrality, thereby supplying an evaluation method for biological weight of the metabolic marker, improving accuracy in identifying the metabolic marker, and realizing high applicability in analyzing other metabolomics platform markers.